Editas Medicine, Inc. (EDIT)

Over the past six months, Editas Medicine's stock has experienced several notable events. In August 2025, the company reported its second-quarter results, showing a loss but exceeding revenue estimates, and announced plans to select a lead development candidate in September 2025, submit an IND application by mid-2026, and achieve human proof-of-concept by the end of 2026. A milestone payment from its collaboration with Bristol Myers Squibb was also triggered. By September 2025, the stock had shown a 107% gain over the preceding six months. In October 2025, news of a competitor freezing a key trial potentially impacted sentiment across the gene-editing sector. In November 2025, Editas announced positive third-quarter results, highlighting preclinical data for EDIT-401 and extending its cash runway into the third quarter of 2027. The company's price target was increased by 22.78% to $4.95 in December 2025. In January 2026, analysts issued various ratings, including a "Hold" from Wells Fargo and an overall "Moderate Buy" consensus. As of February 5, 2026, the closing stock price was $1.67, with a 52-week range between $0.91 and $4.54.

The demand for Editas Medicine's products and services is not typically subject to seasonal fluctuations. Demand is primarily driven by the prevalence of the diseases it aims to treat and the progress and success of its clinical development programs.

Editas Medicine, Inc. focuses on leveraging CRISPR gene editing to correct disease-causing genes. Its major product candidates include EDIT-401, an in vivo program targeting cardiometabolic diseases by aiming to reduce LDL cholesterol levels, which has shown promising preclinical results with over 90% reduction in non-human primates. The company is also advancing EDIT-301 for sickle cell disease and beta-thalassemia. Additionally, Editas Medicine has a collaboration with Bristol Myers Squibb for a CD19 HD Allo CAR T program in oncology.

Editas Medicine, Inc. has its corporate headquarters in Cambridge, Massachusetts, United States and maintains facilities in Boulder, Colorado.

Editas Medicine's brand reputation has been characterized by optimism regarding its scientific advancements and concerns about its financial performance and therapeutic efficacy. The company generally holds a "Buy" or "Moderate Buy" consensus rating from analysts, with some recommending a "Strong Buy" due to its proprietary CRISPR platform and promising clinical trial outcomes. Positive preclinical data for EDIT-401 has also contributed to a favorable view of its pipeline potential. However, a negative outlook exists due to concerns about the efficacy and development risks of its in vivo therapies compared to ex vivo ones. The company's financial health has also been a point of concern, with analysts noting its cash burn and projected negative earnings per share for fiscal year 2025. Changes in executive leadership and the broader gene-editing industry can also influence Editas's reputation.

The ownership structure of Editas Medicine (EDIT) is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 24.77% of the company's stock, with some reports indicating up to 53.33%. Insiders own about 0.55%, while public companies and individual investors collectively hold 74.68%. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and others.